This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OSMT Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT) 30 days 90 days 365 days Advanced Chart Get OSMT alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.98▼$1.4952-Week Range N/AVolume296,500 shsAverage Volume396,682 shsMarket Capitalization$69.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ. Read More Receive OSMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OSMT Stock News HeadlinesVanda Pharmaceuticals Inc.March 6, 2024 | wsj.comRVL Pharmaceuticals PLC (RVLPQ)December 19, 2023 | investing.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 3 at 2:00 AM | Crypto Swap Profits (Ad)Osmotica Pharmaceuticals is about to announce its earnings — here's what to expectAugust 14, 2023 | markets.businessinsider.comWhat Wall Street expects from Osmotica Pharmaceuticals's earningsMarch 19, 2023 | markets.businessinsider.comGRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsJanuary 19, 2022 | nz.finance.yahoo.comUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'January 19, 2022 | benzinga.comSee More Headlines OSMT Stock Analysis - Frequently Asked Questions How were Osmotica Pharmaceuticals' earnings last quarter? Osmotica Pharmaceuticals plc (NASDAQ:OSMT) released its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to the consensus estimate of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%. When did Osmotica Pharmaceuticals IPO? Osmotica Pharmaceuticals (OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO. What other stocks do shareholders of Osmotica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Osmotica Pharmaceuticals investors own include Canopy Growth (CGC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), NIO (NIO), Allena Pharmaceuticals (ALNA) and Endo International (ENDP). Company Calendar Last Earnings11/15/2021Today7/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OSMT CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees302Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.59 million Net Margins-138.76% Pretax Margin-167.59% Return on Equity-81.23% Return on Assets-20.97% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.42 Sales & Book Value Annual Sales$177.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.00 Book Value$1.50 per share Price / BookN/AMiscellaneous Outstanding Shares62,585,000Free Float59,318,000Market Cap$69.47 million OptionableNot Optionable Beta2.34 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:OSMT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osmotica Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Osmotica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.